Literature DB >> 15368045

[Testosterone and the prostate].

H Sperling1, R Rossi, G Lümmen, H Rübben.   

Abstract

Testosterone has a distinct role in benign and malignant diseases of the prostate. Therefore, knowledge about the physiological interactions between testosterone and the prostate and the special circumstances under testosterone substitution are of great impact for urologists.PSA value and prostate volume do not show significant changes under testosterone substitution therapy. Even if there are no long-term studies in men under substitution due to decreased testosterone, the therapy seems to be safe under regular control of the prostate with PSA and sonography, and the risk for prostate carcinoma is not increased. In hypogonadal men with high-grade PIN under testosterone substitution, 1 in 20 cases with suspicious rectal examination exhibited a carcinoma; the PSA values did not show a difference between men with or without PIN.Nevertheless, it remains unclear whether men after successful radical prostatectomy should receive testosterone substitution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15368045     DOI: 10.1007/s00120-004-0654-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

1.  Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.

Authors:  Tom Pickles; Alex Agranovich; Eric Berthelet; Graeme G Duncan; Mira Keyes; Winkle Kwan; Michael R McKenzie; W James Morris
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

2.  Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume.

Authors:  A V Pechersky; V I Mazurov; V F Semiglazov; A I Karpischenko; V V Mikhailichenko; A V Udintsev
Journal:  Int J Androl       Date:  2002-04

3.  Effects of androgen deficiency and replacement on prostate zonal volumes.

Authors:  B Jin; A J Conway; D J Handelsman
Journal:  Clin Endocrinol (Oxf)       Date:  2001-04       Impact factor: 3.478

4.  Association between prostate cancer and serum testosterone levels.

Authors:  Ping L Zhang; Seymour Rosen; Ravindra Veeramachaneni; Jerry Kao; William C DeWolf; Glenn Bubley
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

5.  The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.

Authors:  Fouad K Habib; Margaret Ross; Colin W Bayne; Prasad Bollina; Ken Grigor; Karen Chapman
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

6.  Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency.

Authors:  J Imperato-McGinley; T Gautier; K Zirinsky; T Hom; O Palomo; E Stein; E D Vaughan; J A Markisz; E Ramirez de Arellano; E Kazam
Journal:  J Clin Endocrinol Metab       Date:  1992-10       Impact factor: 5.958

Review 7.  Hormones and prostate cancer: current perspectives and future directions.

Authors:  Ann W Hsing; Juergen K V Reichardt; Frank Z Stanczyk
Journal:  Prostate       Date:  2002-08-01       Impact factor: 4.104

8.  Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates.

Authors:  N Bruchovsky; P S Rennie; F H Batzold; S L Goldenberg; T Fletcher; M G McLoughlin
Journal:  J Clin Endocrinol Metab       Date:  1988-10       Impact factor: 5.958

9.  Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls.

Authors:  H M Behre; J Bohmeyer; E Nieschlag
Journal:  Clin Endocrinol (Oxf)       Date:  1994-03       Impact factor: 3.478

10.  Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.

Authors:  Robert E Gerstenbluth; Prakash N Maniam; Eric W Corty; Allen D Seftel
Journal:  J Androl       Date:  2002 Nov-Dec
View more
  2 in total

Review 1.  [Testosterone substitution therapy in prostate cancer].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2011-08       Impact factor: 0.639

2.  [Testosterone replacement therapy for prostate cancer].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.